Sanofi (NASDAQ:SNY) Shares Bought by Providence Capital Advisors LLC

Providence Capital Advisors LLC increased its position in Sanofi (NASDAQ:SNY) by 0.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 55,001 shares of the company’s stock after buying an additional 201 shares during the quarter. Providence Capital Advisors LLC’s holdings in Sanofi were worth $2,653,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in SNY. Synergy Asset Management LLC bought a new position in shares of Sanofi during the fourth quarter worth about $25,000. McClarren Financial Advisors Inc. raised its holdings in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the period. Lee Danner & Bass Inc. acquired a new position in Sanofi during the fourth quarter valued at $31,000. Sunbelt Securities Inc. grew its position in Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares in the last quarter. Finally, Sierra Ocean LLC acquired a new position in shares of Sanofi in the fourth quarter worth $44,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on SNY shares. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, The Goldman Sachs Group assumed coverage on Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $62.50.

Sanofi Stock Up 0.8 %

Shares of NASDAQ SNY opened at $54.91 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company has a market cap of $139.35 billion, a price-to-earnings ratio of 22.05, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The firm’s 50-day simple moving average is $55.03 and its 200 day simple moving average is $52.85. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.